- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00409227
Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy
Prospective Randomized Placebo Controlled Blinded Study to Evaluate the Efficacy of Alfuzosin (Alpha Blocker) on the Success Rates Following SWL.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All patients undergoing SWL are included in study. Exclusion criteria: Patient with radio-lucent stone, patients treated with calcium channel blockers, alpha blockers, steroids, patients with contraindication to alpha blocker treatment, postural hypotension patents with abnormal liver function tests.
Patient will be recruited to the study prospectively. Following signature on inform consent patients will be randomized into 2 groups. One group will be treated with alfuzosin 10mg a day and the control group with placebo. Treatment will be initiated following the lithotripsy treatment.
Parameters for investigation includes: demographic and personal data, stone size and location (obtained by CT or KUB), pain control medication and visual analogue scale assessment of pain, side effects, clinical squeals, stone free out come. Follow up evaluation will be at 1 week, 1 month, and 3 months post treatment. Success will be defined following CT evaluation at 3 months. Treatment ends at stone free achievement or at 3 months.
Endpoints:Stone free rate, time to stone free, side effect.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Zerifin, Israel, 40700
- Recruiting
- Endourology unit Urology department Assaf Harofeh MC
-
Contact:
- yoram i siegel, MD
- Phone Number: 972-577-345408
- Email: ysiegel@asaf.health.gov.il
-
Principal Investigator:
- Yoram I Siegel, MD
-
Sub-Investigator:
- yaniv shilo, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients undergoing shock wave lithotripsy treatment for urolithiasis.
Exclusion Criteria:
- patients with abnormal liver function, postural hypotension, alpha-blocker treatment, sensitivity to alpha-blockers, radio-lucent stone, calcium channel blocker treatment, steroids treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
double blind placebo control
|
P.O.
alfuzosin 10 mg once a day
|
Placebo Comparator: 2
placebo control blinded arm
|
placebo once a day for 3 months or stone free
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
use of pain control medication stone free rates
Time Frame: 3 months
|
3 months
|
pain visual analogue scale
Time Frame: 3 month
|
3 month
|
side effects
Time Frame: 3 months
|
3 months
|
stone free rate
Time Frame: 3 months
|
3 months
|
time to stone free status
Time Frame: 3 months
|
3 months
|
need for secondary procedures
Time Frame: 3 months
|
3 months
|
auxiliary procedures
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: yoram I siegel, MD, Endourology unit Urology department Assaf harofeh MC.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Kidney Diseases
- Urologic Diseases
- Pathological Conditions, Anatomical
- Ureteral Diseases
- Calculi
- Urinary Calculi
- Urolithiasis
- Kidney Calculi
- Nephrolithiasis
- Ureteral Calculi
- Ureterolithiasis
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Urological Agents
- Adrenergic alpha-1 Receptor Antagonists
- Alfuzosin
- Adrenergic alpha-Antagonists
Other Study ID Numbers
- 165/05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nephrolithiasis
-
Mayo ClinicCompletedNephrolithiasis, Calcium Oxalate | Nephrolithiasis, Calcium PhosphateUnited States
-
University Hospital Inselspital, BerneCompletedCalcium NephrolithiasisSwitzerland
-
University of Texas Southwestern Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)WithdrawnUric Acid NephrolithiasisUnited States
-
University of British ColumbiaRecruiting
-
University of Texas Southwestern Medical CenterRecruitingNephrolithiasis, Uric AcidUnited States
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...RecruitingKidney Calculi | Nephrolithiasis | Urolithiasis | Kidney Stone | Nephrolithiasis, Calcium Oxalate | Oxaluria | Urolithiasis, Calcium Oxalate | Oxalate UrolithiasisUnited States
-
Mahidol UniversityNot yet recruitingSafety Issues | Surgery-Complications | Nephrolithiasis Staghorn CalculusThailand
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...RecruitingHealthy | Kidney Calculi | Nephrolithiasis | Urolithiasis | Kidney Stone | Nephrolithiasis, Calcium Oxalate | Oxaluria | Urolithiasis, Calcium Oxalate | Oxalate UrolithiasisUnited States
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Himalaya...CompletedCystinuria | Nephrolithiasis, Calcium OxalateUnited States
-
Ai PengUnknown
Clinical Trials on Alpha blocker-alfuzosin
-
Unity Health TorontoSanofiWithdrawn
-
SanofiCompleted
-
SanofiCompleted
-
Gangnam Severance HospitalRecruitingProstatic Hyperplasia | Prostatic Hypertrophy | Prostate HyperplasiaKorea, Republic of
-
Singapore General HospitalSanofiWithdrawn
-
Hospital Authority, Hong KongTerminatedProstatic Hyperplasia | Acute Disease | Urinary RetentionChina
-
International Bio serviceNot yet recruiting
-
Samsung Medical CenterThe Korean Urological AssociationWithdrawnBenign Prostatic HyperplasiaKorea, Republic of
-
University Hospitals Cleveland Medical CenterSanofiCompletedErectile Dysfunction | BPHUnited States
-
SanofiCompletedProstatic Hyperplasia | Urinary Retention | Benign Prostatic HypertrophyUnited States, Canada, Poland, Romania, Australia, Netherlands, Portugal, Spain, Sweden, Bulgaria, Denmark, Finland, Hungary, Norway, South Africa, Greece, Israel